EGFR and diffuse midline glioma: Recent studies have documented that in the diffuse midline glioma EGFR mutant, PRC2 inhibition and the consequent H3.3K27me3 loss is related to an epigenetic aberrant overexpression of the EZH2 inhibitory protein EZHIP, instead of to H3F3A variants.